![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
LA Pabreza, S Dhawan and KJ Kellar
Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20007.
Cytisine, a ganglionic agonist, competes with high affinity for brain nicotinic cholinergic receptors labeled by any of several nicotinic 3H- agonist ligands. Here we have examined the binding of [3H]cytisine in rat brain homogenates. [3H]Cytisine binds with high affinity (Kd less than 1 nM), and specific binding represented 60-90% of total binding at all concentrations examined up to 15 nM. The nicotinic cholinergic agonists nicotine, acetylcholine, and carbachol compete with high affinity for [3H]cytisine binding sites, whereas among nicotinic receptor antagonists only dihydro-beta-erythroidine competes with high affinity (in the nanomolar range). Comparison of binding in several brain regions showed that [3H]cytisine binding is higher in the thalamus, striatum, and cortex than in the hippocampus, cerebellum, or hypothalamus. The pharmacology and brain regional distribution of [3H]cytisine binding sites are those predicted for neuronal nicotinic receptor agonist recognition sites. The high affinity and low nonspecific binding of [3H]cytisine should make it a very useful ligand for studying neuronal nicotinic receptors.
This article has been cited by other articles:
|
|
 |
|
  R. S. Bitner, W. H. Bunnelle, D. J. Anderson, C. A. Briggs, J. Buccafusco, P. Curzon, M. W. Decker, J. M. Frost, J. H. Gronlien, E. Gubbins, et al. Broad-Spectrum Efficacy across Cognitive Domains by {alpha}7 Nicotinic Acetylcholine Receptor Agonism Correlates with Activation of ERK1/2 and CREB Phosphorylation Pathways J. Neurosci., September 26, 2007; 27(39): 10578 - 10587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Mega, I. D. Dinov, V. Porter, G. Chow, E. Reback, P. Davoodi, S. M. O'Connor, M. F. Carter, H. Amezcua, and J. L. Cummings Metabolic Patterns Associated With the Clinical Response to Galantamine Therapy: A Fludeoxyglucose F 18 Positron Emission Tomographic Study Arch Neurol, May 1, 2005; 62(5): 721 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Akk and J. H. Steinbach Galantamine Activates Muscle-Type Nicotinic Acetylcholine Receptors without Binding to the Acetylcholine-Binding Site J. Neurosci., February 23, 2005; 25(8): 1992 - 2001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Iida, M. Ogawa, M. Ueda, A. Tominaga, H. Kawashima, Y. Magata, S. Nishiyama, H. Tsukada, T. Mukai, and H. Saji Evaluation of 5-11C-Methyl-A-85380 as an Imaging Agent for PET Investigations of Brain Nicotinic Acetylcholine Receptors J. Nucl. Med., May 1, 2004; 45(5): 878 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Eaton, J.-H. Peng, K. M. Schroeder, A. A. George, J. D. Fryer, C. Krishnan, L. Buhlman, Y.-P. Kuo, O. Steinlein, and R. J. Lukas Characterization of Human {alpha}4{beta}2-Nicotinic Acetylcholine Receptors Stably and Heterologously Expressed in Native Nicotinic Receptor-Null SH-EP1 Human Epithelial Cells Mol. Pharmacol., December 1, 2003; 64(6): 1283 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Stocker, L. De Franceschi, G. A. McNaughton-Smith, R. Corrocher, Y. Beuzard, and C. Brugnara ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice Blood, March 15, 2003; 101(6): 2412 - 2418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Scuvee-Moreau, J.-F. Liegeois, L. Massotte, and V. Seutin Methyl-Laudanosine: A New Pharmacological Tool to Investigate the Function of Small-Conductance Ca2+-Activated K+ Channels J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1176 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Miller, E. H. F. Wong, M. D. Chesnut, and L. P. Dwoskin Reboxetine: Functional Inhibition of Monoamine Transporters and Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 687 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Meyer, L. C. Gahring, and S. W. Rogers Nicotine Preconditioning Antagonizes Activity-dependent Caspase Proteolysis of a Glutamate Receptor J. Biol. Chem., March 22, 2002; 277(13): 10869 - 10875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Parker, S. C. Harvey, and C. W. Luetje Determinants of Agonist Binding Affinity on Neuronal Nicotinic Receptor beta Subunits J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 385 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tizabi, B. Getachew, M. Davila-Garcia, and R. E. Taylor Alcohol preference: association with reduced striatal nicotinic receptors Alcohol Alcohol., July 1, 2001; 36(4): 318 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Mukhin, D. Gündisch, A. G. Horti, A. O. Koren, G. Tamagnan, A. S. Kimes, J. Chambers, D. B. Vaupel, S. L. King, M. R. Picciotto, et al. 5-Iodo-A-85380, an alpha 4beta 2 Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors Mol. Pharmacol., March 1, 2000; 57(3): 642 - 649. [Abstract] [Full Text]
|
|
|
|
|
|
D. C. Perry, M. I. Dávila-García, C. A. Stockmeier, and K. J. Kellar Increased Nicotinic Receptors in Brains from Smokers: Membrane Binding and Autoradiography Studies J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1545 - 1552. [Abstract] [Full Text]
|
|
|
|
|
|
K. Sabey, K. Paradiso, J. Zhang, and J. H. Steinbach Ligand Binding and Activation of Rat Nicotinic alpha 4beta 2 Receptors Stably Expressed in HEK293 Cells Mol. Pharmacol., January 1, 1999; 55(1): 58 - 66. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Parker, A. Beck, and C. W. Luetje Neuronal Nicotinic Receptor beta 2 and beta 4 Subunits Confer Large Differences in Agonist Binding Affinity Mol. Pharmacol., December 1, 1998; 54(6): 1132 - 1139. [Abstract] [Full Text]
|
|
|
|
|
|
M. Zoli, C. Lena, M. R. Picciotto, and J.-P. Changeux Identification of Four Classes of Brain Nicotinic Receptors Using beta 2 Mutant Mice J. Neurosci., June 15, 1998; 18(12): 4461 - 4472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Luetje, F. N. Maddox, and S. C. Harvey Glycosylation within the Cysteine Loop and Six Residues Near Conserved Cys192/Cys193 Are Determinants of Neuronal Bungarotoxin Sensitivity on the Neuronal Nicotinic Receptor alpha 3 Subunit Mol. Pharmacol., June 1, 1998; 53(6): 1112 - 1119. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Marks, K. W. Smith, and A. C. Collins Differential Agonist Inhibition Identifies Multiple Epibatidine Binding Sites in Mouse Brain J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 377 - 386. [Abstract] [Full Text]
|
|
|
|
|
|
M. I. Dávila-García, J. L. Musachio, D. C. Perry, Y. Xiao, A. Horti, E. D. London, R. F. Dannals, and K. J. Kellar [125I]IPH, an Epibatidine Analog, Binds with High Affinity to Neuronal Nicotinic Cholinergic Receptors J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 445 - 451. [Abstract] [Full Text]
|
|
|
|
|
|
H. E. Shannon, M. J. Sheardown, F. P. Bymaster, D. O. Calligaro, N. W. Delapp, J. Gidda, C. H. Mitch, B. D. Sawyer, P. W. Stengel, J. S. Ward, et al. Pharmacology of Butylthio[2.2.2] (LY297802/NNC11-1053): A Novel Analgesic with Mixed Muscarinic Receptor Agonist and Antagonist Activity J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 884 - 894. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. McIntosh, G. O. Corpuz, R. T. Layer, J. E. Garrett, J. D. Wagstaff, G. Bulaj, A. Vyazovkina, D. Yoshikami, L. J. Cruz, and B. M. Olivera Isolation and Characterization of a Novel Conus Peptide with Apparent Antinociceptive Activity J. Biol. Chem., October 13, 2000; 275(42): 32391 - 32397. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
